Skip to content

T · 2914.T · TOBACCO

Japan Tobacco Inc. (2914.T) intrinsic value and stock valuation

$5,265.00as of 2026-11-21 · Mkt cap 10.84T

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Japan Tobacco Inc. DCF and intrinsic value

InvestorsCraft values 2914.T with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from 2914.T’s statements →

Japan Tobacco Inc. Graham Number

Graham Number: $3,871.32d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Consumer Defensive · Tobacco Tokyo 105-6927 jt.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$3.47T+10.6% 5y CAGRd
20112025
Net income
$510.2B+10.5% 5y CAGRd
20112025
Free cash flow
$370.9B-3.1% 5y CAGRd
20112025
Total equity
$4.12T+9.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$3.47T$3.15T$2.84T$2.66T$2.32T
Operating income$770.4B$304.4B$655.7B$661.6B$540.7B
Net income$510.2B$179.2B$482.3B$442.7B$338.5B
EPSd$287.3M$100.9M$271.6M$249.4M$190.7M
Operating cash flow$514.1B$630B$567B$483.8B$598.9B
Capital expenditure-$-143.2B-$-127.77B-$-94.86B-$-81.41B-$-86.35B
Free cash flow$370.9B$502.2B$472.2B$402.4B$512.6B
Total assets$8.42T$8.37T$7.28T$6.55T$5.77T
Total debt$1.68T$1.79T$1.2T$1.02T$979.2B
Net debt$847.6B$705.8B$161.6B$151.8B$257.4B
Total equity$4.12T$3.85T$3.91T$3.62T$2.89T
Cash and short-term investments$831.1B$1.08T$1.04T$866.9B$721.7B
Income statement
20252024202320222021
Revenue$3.47T$3.15T$2.84T$2.66T$2.32T
Cost of revenue$1.52T$1.51T$1.33T$1.21T$1.07T
Gross profit$1.95T$1.64T$1.51T$1.45T$1.26T
Research and development expenses$0.00$78.6B$75.1B$70.8B$65B
Selling, general and administrative expenses$1.18T$1.25T$779.4B$720.2B$653.3B
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$1.18T$1.33T$854.5B$791B$718.3B
Cost and expenses$2.7T$2.85T$2.19T$2T$1.78T
Interest income$67.9B$64.9B$42B$25B$12.4B
Interest expense$195.2B$53.5B$31.7B$36.4B$27.7B
Depreciation and amortization$195.9B$179.7B$179.6B$199.4B$187B
Ebitda$966.3B$454.2B$832.8B$829.2B$687.1B
Operating income$770.4B$304.4B$655.7B$661.6B$540.7B
Total other income/expenses, net-$-30.64B-$-70.58B-$-34.13B-$-68.13B-$-68.34B
Income before tax$739.8B$233.8B$621.6B$593.5B$472.4B
Income tax expense$238.7B$51.2B$136.3B$149.3B$132.2B
Net income$510.2B$179.2B$482.3B$442.7B$338.5B
Weighted average shares outstanding$1.78B$1.78B$1.78B$1.77B$1.77B
Weighted average diluted shares outstanding$1.78B$1.78B$1.78B$1.78B$1.78B
Balance sheet
20252024202320222021
Cash and short-term investments$831.1B$1.08T$1.04T$866.9B$721.7B
Net receivables$640.7B$569B$557.1B$499.1B$475.6B
Inventory$1.06T$957.3B$832.6B$691.9B$563.2B
Total current assets$3.71T$3.58T$3.26T$2.72T$2.32T
Property, plant and equipment, net$979.8B$907.7B$821.5B$776B$755.8B
Goodwill and intangible assets$3.32T$3.4T$2.82T$2.69T$2.37T
Long-term investments$216.9B$206.1B$222.4B$206.8B$155.4B
Total non-current assets$4.71T$4.79T$4.02T$3.82T$3.45T
Total assets$8.42T$8.37T$7.28T$6.55T$5.77T
Accounts payable$711.7B$260B$299.7B$273B$272.3B
Short-term debt$79.6B$201.8B$255.1B$157.6B$161.3B
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.93T$2.15T$1.93T$1.56T$1.5T
Long-term debt$1.6T$1.59T$946.7B$861B$817.8B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.38T$2.37T$1.44T$1.37T$1.39T
Capital lease obligations$0.00$40.4B$37.8B$40B$42.1B
Total liabilities$4.3T$4.52T$3.37T$2.93T$2.89T
Common stock$100B$100B$100B$100B$100B
Retained earnings$3.21T$3.04T$3.19T$3.09T$2.86T
Accumulated other comprehensive income (loss)$526.1B$381.6B$290.5B$104.3B-$-400.09B
Total equity$4.12T$3.85T$3.91T$3.62T$2.89T
Total investments$216.9B$206.1B$222.4B$206.8B$155.4B
Total debt$1.68T$1.79T$1.2T$1.02T$979.2B
Net debt$847.6B$705.8B$161.6B$151.8B$257.4B
Cash flow statement
20252024202320222021
Net income$498B$179.2B$482.3B$442.7B$338.5B
Depreciation and amortization$195.9B$179.7B$179.6B$199.4B$187B
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-295.11B$375.7B-$-64.37B-$-131.65B$56.7B
Accounts receivable-$-33.36B$45.8B-$-30.17B$26.6B-$-29.89B
Inventory-$-121.94B-$-96.57B-$-136.23B-$-93.91B$9.77B
Accounts payable$42.1B-$-46.22B$41B-$-38.25B$111.9B
Net cash provided by operating activities$514.1B$630B$567B$483.8B$598.9B
Investments in property, plant and equipment-$-162.39B-$-150.37B-$-121.21B-$-99.41B-$-102.92B
Acquisitions, net-$-25.47B-$-265.64B$414M$2.99B$41M
Net cash used for investing activities-$-265B-$-439.74B-$-125.72B-$-101.8B-$-97.46B
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-1.62B-$-2M-$-1M-$-1M-$-1M
Dividends paid-$-356.85B-$-349.65B-$-367.33B-$-266.18B-$-251.94B
Net cash used for financing activities-$-475.46B-$-94.94B-$-270.91B-$-306.2B-$-353.18B
Net change in cash-$-253.43B$44.4B$173.3B$145.2B$182.9B
Cash at end of period$831.1B$1.08T$1.04T$866.9B$721.7B
Operating cash flow$514.1B$630B$567B$483.8B$598.9B
Capital expenditure-$-143.2B-$-127.77B-$-94.86B-$-81.41B-$-86.35B
Free cash flow$370.9B$502.2B$472.2B$402.4B$512.6B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Japan Tobacco Inc.

        Japan Tobacco Inc., a tobacco company, manufactures and sells tobacco products, prescription drugs, and processed foods in Japan and internationally. The company operates through four segments: Domestic Tobacco, International Tobacco, Pharmaceutical, and Processed Food. It offers tobacco products, such as cigarettes, cigars, pipe tobacco, oral tobacco, waterpipe tobacco, kretek, and fine cut products under the Winston, Camel, MEVIUS, and LD brands. The company also provides reduced-risk products, including tobacco-infused vapor and heated tobacco products, E-Vapor products, etc. under the Ploom, Logic, Ploom TECH, Ploom TECH+, and Ploom S brands. In addition, it researches and develops, manufactures, and sells prescription drugs for the therapeutic areas, such as cardiovascular, renal and metabolism, immunology, and neuroscience. Further, the company provides staple food products, such as frozen noodles and okonomiyaki, and frozen and packed cooked rice; ambient processed foods; bakery products; and seasonings, including yeast extracts and oyster sauce. Japan Tobacco Inc. was founded in 1898 and is headquartered in Tokyo, Japan.

        CEO
        Kei Nakano
        Employees
        53.59K
        Beta
        0.14

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Japan Tobacco Inc. (2914.T)?

        InvestorsCraft does not currently publish an intrinsic value for 2914.T. How the IC value is calculated.

        Is 2914.T undervalued?

        InvestorsCraft does not publish an undervaluation signal for 2914.T at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.